Drug Solubilization and Stabilization by Cyclodextrin Drug Carriers

Drug Delivery Strategies for Poorly Water-Soluble Drugs

Volumn , Issue , 2013, Pages 67-101

  Loftsson, Thorsteinn ^a   Brewster, Marcus E ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Complexation; Complexation efficiency; Cyclodextrin; Cyclodextrin drug stabilization; Cyclodextrin monograph; Permeation; Pharmacokinetics; Phase solubility diagram; Stability constant; Toxicity

Indexed keywords

EID: 84887223190     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118444726.ch3     Document Type: Chapter

References (178)

1. A. Villiers, Sur la fermentation de la fécule par l'action du ferment butyrique. Compt Rend Acad Sci, 112, 536-538 (1891).
2. T. Loftsson, D. Ducĥene, Cyclodextrins and their pharmaceutical applications. Int J Pharm, 329, 1-11 (2007).
3. F. Schardinger, Über Thermophile Bakterien aus verschiedenen Speisen und Milch, sowie über einige Umsetzungsprodukte derselben in kohlenhydrathältigen Nährlösungen, darunter krystallisierte Polysaccharide (Dextrine) aus Stärke. Z Untersuch Nahr u Genussm, 6, 865-880 (1903).
4. K. Freudenberg, R. Jacobi, Über Schardinger Dextrine aus Star̈ke. Liebigs Ann Chem, 518, 102-108 (1935).
5. K. Freudenberg, F. Cramer, Die Konstitution der Schardinger-Dextrine a, b und g. Z Naturforsch, 3b, 464 (1948).
6. D. French, A.O. Pulley, J.A. Effenberger, M.A. Rougvie, M. Abdullah, Studies on the Schardinger dextrins. XII. The molecular size and structure of the d-, e-, z-, and h-dextrins. Arch Biochem Biophys, 111, 153-160 (1965).
7. K.L. Larsen, Large cyclodextrins. J Incl Phenom Macroc Chem, 43, 1-13 (2002).
8. H. Ueda, T. Endo, H. Nagase, S. Kobayashi, T. Nagai, Isolation, purification, and characterization of cyclomaltodecaose. in Proceedings of the Eighth International Symposium on Cyclodextrins, Szejtli, J., Szente, L. (eds). Dordrecht: Kluwer Academic Publishers, pp. 17-20 (1996).
9. H. Ueda, T. Endo, Large-ring cyclodextrins, in Cyclodextrins and their Complexes: Chemistry, Analytical Methods, Applications, Dodziuk, H. (ed.), Weinheim: Wiley-VCH Verlag, pp. 370-380 (2006).
10. K. Freudenberg, F. Cramer, H. Plieninger, Verfahren zur Herstellung von Einschlußverbindungen physiologisch wirksamer organischer Verbindungen. Knoll A.-G. Chemische Fabriken (1953).
11. F. Cramer, Einschlussverbindungen. Berlin: Springer-Verlag (1954).
12. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol, 62, 1607-1621 (2010).
13. J. Blanchard, S. Proniuk, Some important considerations in the use of cyclodextrins. Pharm Res, 16, 1796-1798 (1999).
14. K.H. Frömming, J. Szejtli, Cyclodextrins in Pharmacy. Dordrecht: Kluwer Academic Publishers (1994).
15. J. Szejtli, Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers (1988).
16. F. Hirayama, M. Yamamoto, K. Uekama, Acid-catalyzed hydrolysis of maltosyl-β-cyclodextrin. J Pharm Sci, 81, 913-916 (1992).
17. S. Buedenbender, G.E. Schulz, Structural base for enzymatic cyclodextrin hydrolysis. J Mol Biol, 385, 606-617 (2009).
18. J. Szejtli, The metabolism, toxicity and biological effects of cyclodextrins, in Ducĥene, D. (ed.), Cyclodextrins and Their Uses. Paris: Editions de Santé, pp. 173-212 (1987).
19. I.C. Munro, P.M. Newberne, R.R.Young, A.Bär, Safety assessment of γ-cyclodextrin. Regul Toxicol Pharmacol, 39(Suppl. 1), S3-S13 (2004).
20. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci, 86(2), 147-162 (1997).
21. V.J. Stella, Q. He, Cyclodextrins. Tox Pathol, 36, 30-42 (2008).
22. G. Antlsperger, G. Schmid, Toxicological comparison of cyclodextrins. In Szejtli, J., Szente, L., editors. Proceedings of the Eighth International Symposium on Cyclodextrins. Budapest, Hungary, March 30-April 2, 1996, ed., Dordrecht: Kluwer Academic Publishers, pp. 149-155 (1996).
23. G. Antlsperger, New aspects in cyclodextrin toxicology. In Hedges, A.R. (ed.), Minutes of the Sixth International Symposium on Cyclodextrins, Paris: Editions de Santé. pp. 277-283 (1992).
24. A.T.H.J. De Bie, B. van Ommen, A. Bär, Disposition of 14C-γ-cyclodextrin in germfree and conventional rats. Regul Toxicol Pharmacol, 27, 150-158 (1998).
25. B. Van Ommen, A.T.H.J. De Bie, A. Bär, Disposition of 14C-α-cyclodextrin in germ-free and conventional rats. Regul Toxicol Pharmacol, 39, S57-S66 (2004).
26. H. Zhou, M. Goldman, J. Wu, R. Woestenborghs, A.E. Hassell, P. Lee, A. Baruch, L. Pesco-Koplowitz, J. Borum, L.J. Wheat, A pharmacokinetic study of intravenous intraconazole followed by oral administration of intraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol, 38, 593-602 (1998).
27. T. Higuchi, K.A. Connors, Phase-solubility techniques, Adv Anal Chem Instrum, 4, 117-212 (1965).
28. A.J. Repta, Alteration of apparent solubility through complexation. InYalkowski, S.H. (ed.) Techniques of Solubilization of Drugs. New York: Marcel Dekker, pp. 135-157 (1985).
29. M.E. Brewster, T. Loftsson, Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 59, 645-666 (2007).
30. M.E. Brewster, T. Loftsson, Complexation: Use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations. In Gupta, P.K., Brazeau, G.A. (eds), injectable Drug Development Techniques to Reduce Pain and Irritation. Denver: Interpharm Press, pp. 307-336 (1999).
31. A. Wu, X. Shen, Y. He, Investigation of γ-cyclodextrin nanotube induced by N,N-diphenylbenzidine molecule. J Coll Interf Sci, 297, 525-533 (2006).
32. A. Wu, X. Shen, Y. He, Micrometer-sized rodlike structure formed by the secondary assembly of cyclodextrin nanotube. J Coll Interf Sci, 302, 87-89 (2006).
33. M. Bonini, S. Rossi, G. Karlsson, M. Almgren, P. Lo Nostro, P. Baglioni, Selfassembly of β-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir, 22, 1478-1484 (2006).
34. P. Jansook, S.V. Kurkov, T. Loftsson, Cyclodextrins as solubilizers: formation of complex aggregates. J Pharm Sci, 99, 719-729 (2010).
35. P. Jansook, M.D. Moya-Ortega, T. Loftsson, Effect of self-aggregation of γ-cyclodextrin on drug solubilization. J Incl Phenom Macroc Chem, 68, 229-236 (2010).
36. M. Messner, S.V.Kurkov, P. Jansook, T. Loftsson, Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm, 387, 199-208 (2010).
37. M. Kajtár, M. Vikmon, E. Morlin, J. Szejtli, Aggregation of amphotericin B in the presence of g-cyclodextrin. Biopolymers, 28, 1585-1596 (1989).
38. A.W. Coleman, I. Nicolis, N. Keller, J.P. Dalbiez, Aggregation of cyclodextrins: an explanation of the abnormal solubility of β-cyclodextrin. J Incl Phenom Macroc Chem, 13, 139-143 (1992).
39. S.A. Andronati, Y.E. Shapiro, L.N. Yakubovskaya, V.Y. Gorbatyuk, K.S. Andronati, S.P. Krasnoschekaya, Inclusion compounds of psychotropic agents and cyclodextrins. J Incl Phenom Macroc Chem, 24, 175-186 (1996).
40. V. Gabelica, N. Galic, E. De Pauw, On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry. J Am Soc Mass Spectrom, 13, 946-953 (2002).
41. I. Correia, N. Bezzenine, N. Ronzani, N. Platzer, J.-C. Beloeil, B.-T. Doan, Study of inclusion complexes of acridine with b-and (2,6-di-O-methyl)-b-cyclodextrin by use of solubility diagrams and NMR spectroscopy. J Phys Org Chem, 15, 647-659 (2002).
42. T. Loftsson, M. Másson, M.E. Brewster, Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci, 93, 1091-1099 (2004).
43. Z. Bikádi, R. Kurdi, S. Balogh, J. Szemán, E. Hazai, Aggregation of cyclodextrins as an important factor to determine their complexation behavior. Chem Biodiv, 3, 1266-1276 (2006).
44. P.Yan, J.-N. Tang, J.-X. Xiao, Interaction between β-cyclodextrin and mixed cationicanionic surfactants (2): aggregation behavior. J Dispers Sci Technol, 28, 623-626 (2007).
45. M. Messner, S.V. Kurkov, M.E. Brewster, P. Jansook, T. Loftsson, Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes. Int. J. Pharm, 407, 174-183 (2011).
46. M. Messner, S.V. Kurkov, R. Flavià-Piera, M.E. Brewster, T. Loftsson, Self-assembly of cyclodextrin complexes: The effect of the guest molecule (manuscript) (2011).
47. T. Loftsson, D. Hreinsdóttir, M. Másson, Evaluation of cyclodextrin solubilization of drugs. Int J Pharm, 302, 18-28 (2005).
48. J.M. Adam, D.J. Bennett, A. Bom, J.K. Clark, H. Feilden, E.J. Hutchinson, R. Palin, A. Prosser, D.C. Rees, G.M. Rosair, D. Stevenson, M.-Q. Zhang, Cyclodextrinderived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem, 45, 1806-1816 (2002).
49. C.S. Perry, S.A. Charman, R.J. Prankerd, F.C.K. Chiu, M.J. Scanlon, D. Chalmers, W.N. Charman, The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins. J Pharm Sci, 95, 146-158 (2006).
50. L. Szente, J. Szejtli, G.L. Kis, Spontaneous opalescence of aqueous γ-cyclodextrin solutions: complex formation or self-aggregation. J Pharm Sci, 87, 778-781 (1998).
51. L. Szente, J. Szejtli, Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev, 36, 17-28 (1999).
52. G. González-Gaitano, P. Rodríguez, J.R. Isasi, M. Fuentes, G. Tardajos, M. Sánchez, The aggregation of cyclodextrins as studied by photon correlation spectroscopy. J Incl Phenom Macrocycl Chem, 44, 101-105 (2002).
53. W. He, P. Fu, X.H. Shen, H.C. Gao, Cyclodextrin-based aggregates and characterization by microscopy. Micron, 39, 495-516 (2008).
54. T. Loftsson, A. Magnúsdóttir, M. Másson, J.F. Sigurjónsdóttir, Self-association and cyclodextrin solubilization of drugs. J Pharm Sci, 91, 2307-2316 (2002).
55. A. Magnusdottir, M. Másson, T. Loftsson, Self association and cyclodextrin solubilization of NSAIDs. J Incl Phenom Macroc Chem, 44, 213-218 (2002).
56. H.H. Sigurdsson, A. Magnusdottir, M. Masson, T. Loftsson. The effects of cyclodextrins on hydrocortisone permeability through semi-permeable membranes. J Incl Phenom Macrocycl Chem, 44, 163-167 (2002).
57. P.D. Ross, M.V. Rekharsky, Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes. Biophys J, 71, 2144-2154 (1996).
58. R.I. Gelb, L.M. Schwartz, B. Cardelino, H.S. Fuhrman, R.F. Johnson, D.F. Laufer, Binding mechanisms in cyclohexaamylose complexes. J Am Chem Soc, 103, 1750-1757 (1981).
59. R.I. Gelb, L.M. Schwartz, M. Radeos, D.A. Laufer, Cycloamylose complexation of organic anions. J Phys Chem, 87, 3349-3354 (1982).
60. M.V. Rekharsky, R.N. Goldberg, F.P. Schwarz, Y.B. Tewari, P.D. Ross, Y. Yamashoji, Y. Inoue, Thermodynamic and nuclear magnetic resonance study of the interactions of α-and β-cyclodextrin with model substances: phenethylamine, ephedrines, and related substances. J Am Chem Soc, 145, 8830-8840 (1995).
61. M.V. Rekharsky, F.P. Schwarz,Y.B. Tewari, R.N. Goldberg, M. Tanaka,Y.Yamashoji, Thermodynamic and NMR study of the inclusions of cyclodextrins with cyclohexane derivatives. J Phys Chem, 98, 4098-4103 (1994).
62. W. Saenger, Cyclodextrin inclusion compounds in research and industry. AngewChem Int Ed Engl, 19, 344-362 (1980).
63. L. Liu, Q.-X. Guo, The driving forces in the inclusion complexation of cyclodextrins. J Incl Phenom Macroc Chem, 42, 1-14 (2002).
64. T. Loftsson, Effects of cyclodextrins on chemical stability of drugs in aqueous solutions. Drug Stability, 1, 22-33 (1995).
65. P.W. Wertz, Stratum corneum lipids and water. Exog Dermatol, 3, 53-56 (2004).
66. R. Bansil, B.S. Turner, Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci, 11, 164-170 (2006).
67. H. Lennernäs, Human intestinal permeability. J Pharm Sci, 87, 403-410 (1998).
68. J.P. Karlsson, P. Artursson, A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelia (Caco-2) cells grown in permeable filter chambers. Int J Pharm, 71, 55-64 (1991).
69. K.A. Youdim, A. Avdeef, N.J. Abbott, In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 8, 997-1003 (2003).
70. A. Avdeef, P.E. Nielsen, O. Tsinman, PAMPA: A drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci, 22, 365-374 (2004).
71. M.E. Brewster, M. Noppe, J. Peeters, T. Loftsson, Effect of the unstirredwater layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm, 342, 250-253 (2007).
72. T. Higuchi, Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem, 11(2), 85-97 (1960).
73. G.L. Flynn, O.S. Carpender, S.H. Yalkowsky, Total mathematical resolution of diffusion layer control of barrier flux. J Pharm Sci, 61, 312-314 (1972).
74. G.L. Flynn, S.H. Yalkowsky, Correlation and prediction of mass transport across membranes I: influence of alkyl chain length on flux-determining properties of barrier and diffusant. J Pharm Sci, 61, 838-852 (1972).
75. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol, 63, 1119-1135 (2011).
76. T. Loftsson, S.B. Vogensen, M.E. Brewster, F. Konrásdóttir, Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci, 96, 2532-2546 (2007).
77. K. Khanvilkar, M.D. Donovan, D.R. Flanagan, Drug transfer through mucus. Adv Drug Deliv Rev, 48, 173-193 (2001).
78. T. Loftsson, H.H. Sigursson, F. Konrásdóttir, S. Gísladóttir, P. Jansook, E. Stefánsson, Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie, 63, 171-179 (2008).
79. A. Preiss, W. Mehnert, K.H. Frömming, In-vitro hydrocortisone release from ointments in presence of cyclodextrins. Pharmazie, 49, 902-906 (1994).
80. A. Preiss, W. Mehnert, K.-H. Frömming, Penetration of hydrocortisone into excised human skin under the influence of cyclodextrins. Pharmazie, 50, 121-126 (1995).
81. J. Pitha, T. Hoshino, J. Torres-Labandeira, T. Irie, Preparation of drug: hydroxypropylcyclodextrin complexes by method using ethanol or aqueous ammonium hydroxide as co-solubilizers. Int J Pharm, 80, 253-258 (1992).
82. J. Pitha, T. Hoshino, Effects of ethanol on formation of inclusion complexes of hydroxypropylcyclodextrins with testosterone or with methyl organe. Int J Pharm, 80, 243-251 (1992).
83. T. Loftsson, M. Másson, J.F. Sigurjónsdóttir, Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci, 9, 237-242 (1999).
84. V.J. Stella, R.A. Rajewski, Cyclodextrins: their future in drug formulation and delivery. Pharm Res, 14(5), 556-567 (1997).
85. T. Loftsson, F. Konrásdóttir, M. Másson, Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes. Pharmazie, 61, 83-89 (2006).
86. J.D. Artiss, K. Brogan, M. Brucal, M. Moghaddam, K.-L.C. Jen, The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metab Clin Exp, 55, 195-202 (2006).
87. H.M. Cabral Marques, J. Hadgraft, I.W. Kellaway, G. Taylor, Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β-and HP-β-cyclodextrins in rabbits. Int J Pharm, 77, 297-302 (1991).
88. A. Hussain, J.J. Arnold, M.A. Khan, F. Ahsan, Absorption enhancers in pulmonary protein delivery. J Control Rel, 94, 15-24 (2004).
89. B. Evrard, P. Bertholet, M. Gueders, M-P. Flament, G. Piel, L. Delattre, A. Gayot, P. Leterme, J.-M. Foidart, D. Cataldo, Cyclodextrins as a potential carrier in drug nebulization. J Control Rel, 96, 403-410 (2004).
90. T. Sato, K. Mizuno, F. Ishii, A novel administration route of edaravone-II: mucosal absorption of edaravone from edaravone/hydroxypropyl-β-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite. Pharmacology, 85, 88-94 (2010).
91. J.K. Kim, M.S. Kim, J.S. Park, C.K. Kim, Thermo-reversible flurbiprofen liquid suppository with HP-β-CD as a solubility enhancer: improvement of rectal bioavailability. J Incl Phenom Macroc Chem, 64, 265-272 (2009).
92. M. Francois, E. Snoeckx, P. Putteman, F. Wouters, E. De Proost, U. Delaet, J. Peeters, M.E. Brewster, A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci, 5(1), Article Number: 5 www.aapsj.org/view.asp?art=ps050105 (2003).
93. E. Cevher, D. Sȩnsoy, M. Zloh, L. Mülazimoǧlu, Preparation and characterisation of natamycin: γ-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations. J Pharm Sci, 97, 4319-4335 (2008).
94. M.F. Sugrue, The pharmacology of antiglaucoma drugs. Pharm Ther, 43, 91-138 (1989).
95. P. Jansook, E. Stefánsson, M. Thorsteinsdóttir, B.B. Sigurdsson, S.S. Kristjánsdóttir, J.F. Bas, H.H. Sigurdsson, T. Loftsson, Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm, 76, 208-214 (2010).
96. T. Järvinen, K. Järvinen, A. Urtti, D. Thompson, V.J. Stella, Sulfobutyl ether β-cyclodextrin (SBE-β-CyD) in eye drops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J Ocul Pharmacol Ther, 11, 95-106 (1995).
97. P. Jarho, K. Järvinen, A. Urtti, V.J. Stella, T. Järvinen, Modified β-cyclodextrin (SBE7-β-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J Pharm Pharmacol, 48, 264-270 (1996).
98. P. Suhonen, T. Jarvinen, K. Lehmussaari, T. Reunamaki, A. Urtti, Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharmaceutical Research, 12, 529-533 (1995).
99. M. Tanaka, Y. Iwata, Y. Kouzuki, K. Taniguchi, H. Matsuda, H. Arima, S. Tsuchiya, Effect of 2-hydroxypropyl-β-cyclodextrin on percutaneous absorption of methyl paraben. J Pharm Pharmacol, 47, 897-900 (1995).
100. F. Konrádsdóttir, H. Ogmundsdóttir, V. Sigurdsson, T. Loftsson, Drug targeting to the hair follicles: a cyclodextrin based drug delivery. AAPS PharmSciTech, 10, 266-269 (2009).
101. L.A. Felton, C.J. Wiley, D.A. Godwin, Influence of hydroxypropyl-β-cyclodextrin on transdermal permeation and skin accumulation of oxybenzone. Drug Devel Ind Pharm, 28, 1117-1124 (2002).
102. J. Yang, C.J. Wiley, D.A. Godwin, L.A. Felton, Influence of hydroxypropyl-β-cyclodextrin on transdermal penetration and photostability of avobenzone. Eur J Pharm Biopharm, 69, 605-612 (2008).
103. L.A. Felton, C.J.Wiley, D.A. Godwin, Influence of cyclodextrin complexation on the in vivo photoprotective effects of oxybenzone. Drug Devel Ind Pharm, 30, 95-102 (2004).
104. V. Sarveiya, J.F. Templeton, H.A.E. Benson, Inclusion complexation of the sunscreen 2-hydroxy-4-methoxy benzophenone (oxybenzone) with hydroxypropyl-β-cyclodextrin: effect on membrane diffusion. J Incl Phenom Macroc Chem, 49, 275-281 (2004).
105. R.G. Strickley, Solubilizing excipients in oral and injectable formulations. Pharm Res, 21, 201-230 (2004).
106. L.A. Trissel (ed.), Handbook on Injectable Drugs. 12th edn. Bethesda, MD: American Society of Health-System Pharmacists (2003).
107. V.J. Stella, V.M. Rao, E.A. Zannou, V. Zia, Mechanism of drug release from cyclodextrin complexes, Adv Drug Deliv Rev, 36, 3-1 (1999).
108. S.V. Kurkov, T. Loftsson, M. Messner, D. Madden, Parenteral delivery of HPβCD: effects on drug-HSA binding. AAPS PharmSciTech, 11, 1152-1158 (2010).
109. G. Piel, B. Evrard, T. Van Hees, L. Delattre, Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm, 180, 41-45 (1999).
110. J. Liu, L. Qiu, J. Gao, Y. Jin, Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int J Pharm, 312, 137-143 (2006).
111. B.W. Muller, E. Alberts, Effect of hydrotropic substances on the complexation of sprangly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs. J Pharm Sci, 80, 599-604 (1991).
112. T.D. Egan, S.E. Kern, K.B. Johnson, N.L. Pace, The pahrmacokinetics and pharmacodynamics of propofol in modified cyclodextrin formulation (Captisol®) versus propofol in a lipid formulation (Diprivan®): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg, 97, 72-79 (2003).
113. T.R. Buggins, P.A. Dickinson, G. Taylor, The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev, 59, 1482-1503 (2007).
114. V.J. Stella, H.K. Lee, D.O. Thompson, The effect of SBE4-β-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: comparison to a co-solvent solution and a water-soluble prodrug. Int J Pharm, 120, 197-204 (1995).
115. M.P. McIntosh, N. Schwarting, R.A. Rajewski, In vitro and in vivo evaluation of a sulfobutyl ether β-cyclodextrin enabled etomidate formulation. J Pharm Sci, 93, 2585-2594 (2004).
116. Z. Zuo, Y.K. Tam, J. Diakur, L.I. Wiebe, Hydroxypropyl-b-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharmaceut Sci, 5, 292-298 (2002).
117. M. Welliver, New drug sugammadex: A selective relaxant binding agent. AANA Journal, 74, 357-363 (2006).
118. S.A. Charman, C.S. Perry, F.C.K. Chiu, K.A. McIntosh, R.J. Prankerd,W.N. Charman, Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci, 95, 256-267 (2006).
119. B.A.R. Lina, A. Bär, Subchronic oral toxicity studies with a-cyclodextrin in rats. Regul Toxicol Pharmacol, 39, S14-S26 (2004).
120. B.A.R. Lina, A. Bär, Subchronic (13-week) oral toxicity study of a-cyclodextrin in dogs, Regul Toxicol Pharmacol, 39, S27-S33 (2004).
121. M.E. Bellringer, T.G. Smith, R. Read, C. Gopinath, P. Oliver, β-Cyclodextrin: 52-week toxicity studies in the rat and dog, Food Chem Toxicol, 33, 367-376 (1995).
122. S. Gould, R.C. Scott, 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD): a toxicology review. Food Chem Toxicol, 43, 1451-1459 (2005).
123. D.O. Thompson, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst, 14, 1-104 (1997).
124. K. Uekama, Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull, 52, 900-915 (2004).
125. H. Dodziuk (ed.), Cyclodextrins and their Complexes. Weinheim:Wiley-VCH Verlag (2006).
126. E. Sabadini, T. Cosgrove, F.C. Egídio, Solubility of cyclomaltooligosaccharides (cyclodextrins) in H2O and D2O: a comparative study. Carbohydr Res, 341, 270-274 (2006).
127. K.A. Connors, Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci, 84, 843-848 (1995).
128. K.A. Connors, The stability of cyclodextrin complexes in solution. Chem Rev, 97, 1325-1357 (1997).
129. T. Loftsson, H. Fridriksdottir, A.M. Sigurdardottir, H. Ueda, The effect of watersoluble polymers on drug-cyclodextrin complexation. Int J Pharm, 110, 169-177 (1994).
130. F.A. Menard, M.G. Dedhiya, C.T. Rhodes, Studies of the effect of pH, temperature and ring size on the complexation of phenytoin with cyclodextrins. Pharm Acta Helv, 63, 303-308 (1988).
131. G.P. Bettinetti, P. Mura, A. Liguori, G. Bramanti, F. Giordano, Solubilization and interaction of naproxen with cyclodextrinsin aqueous solution and in the solid state. Farmaco, 44, 195-213 (1989).
132. T.-X. Xiang, B.D. Anderson, Inclusion complexes of purine nucleosides with cyclodextrins. 2. Investigation of inclusion complex-geometry and cavity microenvironment. Int J Pharm, 59, 45-55 (1990).
133. F.A. Menard, M.G. Dedhiya, C.T. Rhodes, Physicochemical aspects of the complexation of some drugs with cyclodextrins. Drug Devel Ind Pharm, 16, 91-113 (1990).
134. G. Bettinetti, P. Mura, M.T. Faucci, M. Sorrent, M. Setti, Interaction of naproxen with noncrystalline acetyl β-and acetyl γ-cyclodextrins in the solid and liquid state. Eur J Pharm Sci, 15, 21-29 (2002).
135. T. Loftsson, B.J. Ólafsdot́tir, H. Fridriksdot́tir, S. Jońsdot́tir, Cyclodextrin complexation of NSAIDS: physicochemical characteristics. Eur J Pharm Sci, 1, 95-101 (1993).
136. P. Mura, M.T. Faucci, G.P. Bettinetti, The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-β-cyclodextrin. Eur J Pharm Sci, 13, 187-194 (2001).
137. V. Zia, R.A. Rajewski, V.J. Stella, Thermodynamics of binding of neutral molecules to sulfobutyl ether b-cyclodextrins (SBE-β-CDs): the effect of total degree of substitution. Pharm Res, 17, 936-941 (2000).
138. T. Loftsson, N. Bodor, Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β-estradiol. Acta Pharm Nord, 1, 185-194 (1989).
139. M.A. Hussain, R.C. Diluccio, M.B. Maurin, Complexation of moricizine with nicotinamide and evaluation of the complexation constants by various methods. J Pharm Sci, 82, 77-79 (1993).
140. R. Krishnamoorthy, A.K. Mitra, Prodrugs for nasal drug delivery. Adv Drug Deliv Rev, 29, 135-146 (1998).
141. P. Li, E. Tabibi, S.H. Yalkowsky, Combined effect of complexation and pH on solubilization. J Pharm Sci, 87, 1535-1537 (1998).
142. G. Piel, B. Evrard, M. Fillet, G. Llabres, L. Delattre, Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins. Int J Pharm, 169, 15-22 (1998).
143. E. Redenti, L. Szente, J. Szejtli, Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci, 90, 979-986 (2001).
144. G. Granero, C. Granero, M. Longhi, The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-β-cyclodextrin. Eur J Pharm Sci, 20, 285-293 (2003).
145. T. Loftsson, H.H. Sigursson, M. Másson, N. Schipper, Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie, 59, 25-29 (2004).
146. A.Y. Tinwalla, B.L. Hoesterey, T.-X. Xiang, K. Lim, B.D. Anderson, Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm Res, 10, 1136-1143 (1993).
147. A. Selva, E. Redenti, P. Ventura, M. Zanol, B. Casetta, Study of β-cyclodextrinketakonazole-tartaric acid multicomponent non-covalent association by positive and netagive ionspray mass spectrometry. J Mass Sepectrom, 33, 729-734 (1998).
148. E. Fenyvesi, M. Vikmon, J. Szeman, E. Redenti, M. Delcanale, P. Ventura, J. Szejtli, Interaction of hydoxy acids with β-cyclodextrin. J Incl Phenom Macroc Chem, 33, 339-344 (1999).
149. E. Redenti, L. Szente, J. Szejtli, Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J Pharm Sci, 89, 1-8 (2000).
150. P. Mura, F. Maestrelli, M. Cirri, Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and aminoacids. Int J Pharm, 260, 293-302 (2003).
151. T. Loftsson, Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers. Pharmazie, 53, 733-740 (1998).
152. T. Loftsson, M. Másson, The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Del Sci Tech, 14, 35-43 (2004).
153. T. Yamakawa, S. Nishimura, Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin. J Control Rel, 86, 101-113 (2003).
154. T. Furuta, H. Yoshii, A. Miyamoto, A. Yasunishi, H. Hirano, Effects of water of inclusion complexes of d-limonene and cyclodextrins, Supramolecular Chemistry, 1, 321-325 (1993).
155. P. Li, L. Zhao, S.H. Yalkowsky, Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci, 88, 1107-1111 (1999).
156. V. Zia, R.A. Rajewski, V.J. Stella, Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-β-CD to HP-β-CD. Pharm Res, 18, 667-673 (2001).
157. T. Loftsson, Í.B. Össurardot́tir, M. Duan, N. Zhao, T. Thorsteinsson, M. Maśson, Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: effect of ionization and polymers. J Incl Phenom Macroc Chem, 52, 109-117 (2005).
158. T. Loftsson, P. Jarho, M. Másson, T. Järvinen, Cyclodextrins in drug delivery. Expert Opin Drug Deliv, 2, 335-351 (2005).
159. A. Figueiras, J. Hombach, F. Veiga, A. Bernkop-Schnürch, In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm, 71, 339-345 (2009).
160. M. Jug, M. Bećirević-Laćan, S. Bengez, Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug Devel Ind Pharm, 35, 796-807 (2009).
161. J. Mannila, K. Jarvinen, J. Holappa, L. Matilainen, S. Auriola, P. Jarho, Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. Int J Pharm, 381, 19-24 (2010).
162. S.D. Yoo, B.M. Yoon, H.S. Lee, K.C. Lee, Increased bioavailability of clomipramine after sublingual administration in rats. J Pharm Sci, 88, 1119-1121 (1999).
163. S.I.F. Badawy, M.M. Ghorab, C.M. Adeyeye, Bioavailability of danazolhydroxypropyl-β-cyclodextrin complex by different routes of administration, Int J Pharm, 145, 137-143 (1996).
164. A.C. Jain, B.J. Aungst, M.C. Adeyeye, Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 β-cyclodextrin (SBE 7) complexes, J Pharm Sci, 91, 1659-1668 (2002).
165. T.J. Hoon, M.Y. Dawood, F.S. Khan-Dawood, J. Ramos, R.L. Batenhorst, Bioequivalence of 17β-estradiol hydroxypropyl-β-cyclodextrin complex in postmenopausal women. J Clin Pharmacology, 33, 1116-1121 (1993).
166. H. Fridriksdóttir, T. Loftsson, J.A. Gudmundsson, G.J. Bjarnason, M. Kjeld, T. Thorsteinsson, Design and in vivo testing of 17β-estradiol-HPβCD sublingual tablets, Pharmazie, 51, 39-42 (1996).
167. T. Loftsson, J.A. Gumundsson, R.O. Árnadot́tir, H. Fririksdot́tir, Sublingual delivery of 17β-estradiol from cyclodextrin containing tablets. Pharmazie, 58, 358-359 (2003).
168. W.A.J.J. Hermens, M.J.M. Deurloo, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Mercus, Nasal absorption enhancement of 17β-estradiol by dimethyl-β-cyclodextrin in rabbits and rats. Pharm Res, 7, 500-503 (1990).
169. T. Loftsson, H. Gudmundsdottir, J.F. Sigurjonsdottir, H.H. Sigurdsson, S.D. Sigfusson, M. Masson, E. Stefansson, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm, 212, 29-40 (2001).
170. O. Dale, T. Nilsen, T. Loftsson, H.H. Tønnesen, P. Klepstad, S. Kaasa, T. Holand, P.G. Djupesland, Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharm Pharmacol, 58, 1311-1318 (2006).
171. H. Cabral-Marques, R. Almeida, Optimization of spray-drying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes. Eur J Pharm Biopharm, 73, 121-129 (2009).
172. T. Kinnarinen, P. Jarho, K. Järvinen, T. Järvinen, Pulmonary deposition of a budesonide/γ-cyclodextrin complex in vitro, J Control Rel, 90, 197-205 (2003).
173. L. Matilainen, K. Jarvinen, T. Toropainen, E. Nasi, S. Auriola, T. Jarvinen, P. Jarho, In vitro evaluation of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin, A. Int J Pharm, 318, 41-48 (2006).
174. W. Yang, K.T. Chow, B. Lang, N.P. Wiederhold, K.P. Johnston, R.O. Williams, In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution, Eur J Pharm Sci, 39, 336-347 (2010).
175. D.O. Thompson, G.L. Mosher, Formulations Containing propofol and a Sulfoalkyl Ether Cyclodextrin. ed., US: Cydex, InC. (2006).
176. M.E. Davis, M.E. Brewster, Cyclodextrin-based pharmaceutics: Past, present and future. Nature Rev, 3, 1023-1035 (2004).
177. FDA, Inactive Pharmaceutical Ingredients (2006).
178. FDA, Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (2005).